Table 1 Demographic and clinical characteristics of the study participants.

From: Associations between weight gain, integrase inhibitors antiretroviral agents, and gut microbiome in people living with HIV: a cross-sectional study

 

BIC (n = 32)

DTG (n = 79)

Other (n = 10)

P value

Female sex, n (%)

10 (31.3)

28 (35.4)

5 (50.0)

0.58

Age, mean (SD)

43.0 (9.7)

51.6 (11.6)

53.2 (7.9)

0.0007

Caucasian ethnicity, n (%)

15 (46.9)

47 (59.5)

3 (30.0)

0.15

MSM, n (%)

15 (46.9)

37 (46.8)

2 (20.0)

0.31

BMI, median (IQR)

26.2 (24.0–29.8)

26.9 (23.9–29.4)

30.0 (23.9–31.5)

0.61

Treated diabetes, n (%)

0 (0)

6 (7.6)

0 (0)

0.29

Treated dyslipidemia, n (%)

3 (9.4)

10 (12.7)

4 (40.0)

0.062

CD4 + T-cell count, median (IQR) (cells/mm3)

633 (561–834)

726 (565–877)

691 (468–851)

0.28

Time since HIV diagnosis, mean (SD) (years)

15.5 (8.8)

16.2 (7.7)

15.8 (10.8)

0.92

AIDS diagnosis history, n (%)

19 (59.4)

37 (47.4)

5 (50.0)

0.54

Nadir CD4 + T-cell count, median (IQR) (cells/mm3)

202 (89–336)

237 (125–339)

217 (123–425)

0.87

Days since start of current anchor drug, median (IQR)

803 (721–929)

1876 (637–2239)

1118 (589–1810)

 < 0.0002

ART naïve at start current anchor, n (%)

3 (9.4)

10 (12.7)

0

0.72

Treatment regimen before current anchor, n (%)

   

0.0004

Nonea

3 (9.1)

11 (13.9)

0

NNRTI-based

1 (3.0)

18 (22.8)

0

PI-based

1 (3.0)

17 (21.5)

3 (30.0)

INSTI-based

27 (84.4)

33 (41.8)

7 (70.0)

Change in weight during first year after anchor initiation (kg) (median, IQR)

2.25 (− 0.06–3.25)

0 (− 1.67–2.14)

 − 3.4 (− 5.59–1.27)

0.0038

  1. All variables are reported at the time of stool collection, unless otherwise stated.
  2. AIDS, Acquired Immune Deficiency Syndrome; ART, antiretroviral therapy; BMI, body mass index; HIV, human immunodeficiency virus; INSTI, integrase strand transfer inhibitors; IQR, interquartile range; MSM, men who have sex with men; NNRTI, Non-Nucleoside Reverse Transcriptase Inhibitor; PI, protease inhibitors; SD, standard deviation.
  3. aOne non-naïve patient had interrupted treatment for 3y and 9 months before start of the DTG based regimen.
  4. Significant values are in bold.
Back to article page